Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter

Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall

Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims

Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development

New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)

Apollo HealthCo to raise Rs. 2,475 crore from Advent International

Keimed is a leading wholesale pharma distribution with industry leading operating metrics

AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million

Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery

Bristol Myers Squibb and Cellares inks US$ 380 million capacity reservation for the manufacture of CAR T Cell Therapies

Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use

Evotech and Variant Bio partner to develop fibrosis treatment

Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term

Mac-Chem Products (India)’s Boisar facility renews EU-GMP certification

Alvotech and Teva get US FDA approval of Selarsdi

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva